Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nuclear Medicine Review
MENU
Shortcuts Submit an article Author Guidelines Editorial Board Reviewers 2023

open access

Vol 26 (2023): Continuous Publishing
Review paper
Submitted: 2021-12-01
Accepted: 2022-12-15
Published online: 2023-03-21
View PDF Download PDF file View HTML
Get Citation

Review of current status of targeted alpha therapy in cancer treatment

Tania Jabbar1, Sajid Bashir1, Muhammad Imran Babar1
DOI: 10.5603/NMR.2023.0003
·
Nucl. Med. Rev 2023;26:54-67.
Affiliations
  1. Punjab Institute of Nuclear Medicine, Faisalabad, Pakistan

open access

Vol 26 (2023): Continuous Publishing
Reviews
Submitted: 2021-12-01
Accepted: 2022-12-15
Published online: 2023-03-21

Abstract

Targeted alpha therapy is an emerging alternative for palliative therapy of a wide range of tumor types. Data from preclinicaland clinical research demonstrates a high potential for the selective killing of tumor cells and minimal toxicity to surroundinghealthy tissues. This article summarizes the developmental stages of alpha-targeted therapy from benchtop to commercialization.It discusses fundamental properties, production pathways, microdosimetry, and possible targeting vectors. Proper coverage hasalso been given to comparing it with other standard treatment procedures while exploring clinical applications of alpha emitters.In the end, like other therapies, the challenges it faces and its future impact on personalized medicine are also illustrated.

Abstract

Targeted alpha therapy is an emerging alternative for palliative therapy of a wide range of tumor types. Data from preclinicaland clinical research demonstrates a high potential for the selective killing of tumor cells and minimal toxicity to surroundinghealthy tissues. This article summarizes the developmental stages of alpha-targeted therapy from benchtop to commercialization.It discusses fundamental properties, production pathways, microdosimetry, and possible targeting vectors. Proper coverage hasalso been given to comparing it with other standard treatment procedures while exploring clinical applications of alpha emitters.In the end, like other therapies, the challenges it faces and its future impact on personalized medicine are also illustrated.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

targeted therapy; cancer; alpha particles; microdosimetry; targeting vectors

About this article
Title

Review of current status of targeted alpha therapy in cancer treatment

Journal

Nuclear Medicine Review

Issue

Vol 26 (2023): Continuous Publishing

Article type

Review paper

Pages

54-67

Published online

2023-03-21

Page views

4441

Article views/downloads

1289

DOI

10.5603/NMR.2023.0003

Bibliographic record

Nucl. Med. Rev 2023;26:54-67.

Keywords

targeted therapy
cancer
alpha particles
microdosimetry
targeting vectors

Authors

Tania Jabbar
Sajid Bashir
Muhammad Imran Babar

References (99)
  1. Yordanova A, Eppard E, Kürpig S, et al. Theranostics in nuclear medicine practice. Onco Targets Ther. 2017; 10: 4821–4828.
    CrossRefPubMed
  2. Moumaris M, Bretagne JM, Abuaf N. Nanomedical devices and cancer theranostics. Open Nanomedicine J. 2020; 6(1): 1–11.
    CrossRef
  3. New Technique to Fight Prostate Cancer: IAEA organizes first-of-a-kind training for Radiopharmacists. https://www.iaea.org/newscenter/news/new-technique-to-fight-prostate-cancer-iaea-organizes-first-of-a-kind-training-for-radiopharmacists (25.11.2021).
  4. Majkowska-Pilip A, Gawęda W, Żelechowska-Matysiak K, et al. Nanoparticles in targeted alpha therapy. Nanomaterials (Basel). 2020; 10(7): 1366.
    CrossRefPubMed
  5. Poty S, Francesconi LC, McDevitt MR, et al. α-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1. J Nucl Med. 2018; 59(6): 878–884.
    CrossRefPubMed
  6. Sartor O, Maalouf BN, Hauck CR, et al. Targeted use of alpha particles: current status in cancer therapeutics. J Nucl Med Radiat Ther. 2012; 3(4).
    CrossRef
  7. Nedrow JR, Josefsson A, Park S, et al. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Res. 2017; 7(1): 57.
    CrossRefPubMed
  8. Darwish RAL, Staudacher AH, Li Y, et al. Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy. Medical Physics. 2016; 43(11): 6145–6153.
    CrossRef
  9. Ackerman NL, Graves EE. The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides. Phys Med Biol. 2012; 57(3): 771–783.
    CrossRefPubMed
  10. Kozempel J, Mokhodoeva O, Vlk M. Progress in targeted alpha-particle therapy. What we learned about recoils release from in vivo generators. Molecules. 2018; 23(3).
    CrossRefPubMed
  11. Hertz B. Dr. Saul Hertz (1905–1950) discovers the medical uses of radioactive iodine: the first targeted cancer therapy. In: Ahmadzadehfar H. ed. Thyroid Cancer - Advances in Diagnosis and Therapy. Intechopen 2016.
  12. Sollini M, Marzo K, Chiti A, et al. The five “W”s and “How” of targeted alpha therapy: Why? Who? What? Where? When? and how? Rendiconti Lincei. Scienze Fisiche Naturali. 2020; 31(2): 231–247.
    CrossRef
  13. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 2012; 33(3): 573–590.
    CrossRefPubMed
  14. Morgenstern A, Apostolidis C, Kratochwil C, et al. An overview of targeted alpha therapy with actinium and bismuth. Curr Radiopharm. 2018; 11(3): 200–208.
    CrossRefPubMed
  15. Allen BJ, Raja C, Rizvi S, et al. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Physics Medicine Biolog. 2007; 52(13): L15–L19.
    CrossRef
  16. Bailly C, Bodet-Milin C, Rousseau C, et al. Pretargeting for imaging and therapy in oncological nuclear medicine. EJNMMI Radiopharm Chem. 2017; 2(1): 6.
    CrossRefPubMed
  17. Tafreshi NK, Doligalski ML, Tichacek CJ, et al. Development of targeted alpha particle therapy for solid tumors. Molecules. 2019; 24(23).
    CrossRefPubMed
  18. Larson SM, Carrasquillo JA, Cheung NKV, et al. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015; 15(6): 347–360.
    CrossRefPubMed
  19. Pandit-Taskar N. Targeted radioimmunotherapy and theranostics with alpha emitters. Journal Med Imag Radiation Sci. 2019; 50(4): S41–S44.
    CrossRef
  20. Piktel E, Niemirowicz K, Wątek M, et al. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy. J Nanobiotechnology. 2016; 14(1): 39.
    CrossRefPubMed
  21. Kim JH, Bae C, Kim MJ, et al. A novel nucleolin-binding peptide for cancer theranostics. Theranostics. 2020; 10(20): 9153–9171.
    CrossRefPubMed
  22. Robertson AK, Ramogida CF, Schaffer P, et al. Development of ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm. 2018; 11(3): 156–172.
    CrossRefPubMed
  23. McDevitt MR, Finn RD, Ma D, et al. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med. 1999; 40(10): 1722–1727.
    PubMed
  24. Report Technical Meeting on "Alpha emitting radionuclides and radiopharmaceuticals for therapy" IAEA Headquarters, Vienna, Austria, 2013 June, 24−28.
  25. Poty S, Francesconi LC, McDevitt MR, et al. α-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1. J Nucl Med. 2018; 59(6): 878–884.
    CrossRefPubMed
  26. Elgqvist J, Frost S, Pouget JP, et al. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol. 2014; 3: 324.
    CrossRefPubMed
  27. Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010; 51(2): 311–328.
    CrossRefPubMed
  28. European Cancer Information System ECIS, © European Union, 2019. https://ecis.jrc.ec.europa.eu/ (25.11.2021).
  29. Allen BJ, Huang CY, Clarke RA. Targeted alpha anticancer therapies: update and future prospects. Biologics. 2014; 8: 255–267.
    CrossRefPubMed
  30. Kunikowska J, Królicki L. Targeted α-Emitter therapy of neuroendocrine tumors. Semin Nucl Med. 2020; 50(2): 171–176.
    CrossRefPubMed
  31. Chan HoS, Konijnenberg MW, de Blois E, et al. Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate. EJNMMI Res. 2016; 6(1): 6.
    CrossRefPubMed
  32. Kratochwil C, Giesel FL, Bruchertseifer F, et al. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014; 41(11): 2106–2119.
    CrossRefPubMed
  33. Kratochwil C, Bruchertseifer F, Giesel F, et al. Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015; 56(3): 1232.
  34. Šimeček J, Hermann P, Seidl C, et al. Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics. EJNMMI Res. 2018; 8(1): 78.
    CrossRefPubMed
  35. Phase 1 study of AlphaMedix(TM) in adult subjects with SSTR (+) NET. https://clinicaltrials.gov/ct2/show/NCT03466216 (25.11.2021).
  36. Malcolm J, Falzone N, Lee BQ, et al. Targeted radionuclide therapy: new advances for improvement of patient management and response. Cancers (Basel). 2019; 11(2): 268.
    CrossRefPubMed
  37. Delpassand E, Tworowska I, Shanoon F, et al. First clinical experience using targeted alpha-emitter therapy with 212Pb-DOTAMTATE (AlphaMedix TM) in patients with SSTR(+) neuroendocrine tumors. J Nucl Med. 2019; 60(Suppl.1): 559.
  38. Functionalized silica nanoparticles: development of a combined PET and TAT theranostic agent for NETs. https://netrf.org/research/functionalized-silica-nanoparticles-development-of-a-combined-pet-and-tat-theranostic-agent-for-nets/ (25.11.2021).
  39. Jadvar H, Quinn DI. Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013; 38(12): 966–971.
    CrossRefPubMed
  40. Sartor O, Maalouf BN, Hauck CR. Targeted use of alpha particles: current status in cancer therapeutics. J Nucl Med Radiat Ther. 2012; 3(4).
    CrossRef
  41. de Bono J. Targeted alpha therapy – optimising survival in advanced prostate cancer. Eur Oncol Haematol. 2018; 14(3): 3–10.
  42. Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving ac-psma-617 radioligand therapy. J Nucl Med. 2020; 61(1): 62–69.
    CrossRefPubMed
  43. De Vincentis G, Gerritsen W, Gschwend JE, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019; 30(11): 1728–1739.
    CrossRefPubMed
  44. de Kruijff RM, Drost K, Thijssen L, et al. Improved Ac daughter retention in InPO containing polymersomes. Appl Radiat Isot. 2017; 128: 183–189.
    CrossRefPubMed
  45. Bandekar A, Zhu C, Jindal R, et al. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer. J Nucl Med. 2014; 55(1): 107–114.
    CrossRefPubMed
  46. Gandomani H, Tarazoj A, Siri F, et al. Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors. Biomed Res Therap. 2017; 4(9): 1638–1655.
    CrossRef
  47. Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci (Basel). 2020; 8(1).
    CrossRefPubMed
  48. Seidl C. Targets for therapy of bladder cancer. Semin Nucl Med. 2020; 50(2): 162–170.
    CrossRefPubMed
  49. Pfost B, Seidl C, Autenrieth M, et al. Intravesical α-Radioimmunotherapy with 213bi-anti-egfr-mab defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009; 50(10): 1700–1708.
    CrossRef
  50. Fazel J, Rötzer S, Seidl C, et al. Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma. Cancer Biol Ther. 2015; 16(10): 1526–1534.
    CrossRefPubMed
  51. Autenrieth ME, Seidl C, Bruchertseifer F, et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. Eur J Nucl Med Mol Imaging. 2018; 45(8): 1364–1371.
    CrossRefPubMed
  52. Autenrieth ME, Horn T, Kurtz F, et al. [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure]. Urologe A. 2017; 56(1): 40–43.
    CrossRefPubMed
  53. Morgenstern A, Bruchertseifer F. Development of targeted alpha therapy from bench to bedside. J Med Imag Radiat Sci. 2019; 50(4S1): S18–S20.
    CrossRefPubMed
  54. English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013; 17(2): 85–99.
    CrossRefPubMed
  55. Andersson HK, Cederkrantz E, Bäck T, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. J Nucl Med. 2009; 50(7): 1153–1160.
    CrossRefPubMed
  56. Frantellizzi V, Cosma L, Brunotti G, et al. Targeted alpha therapy with Thorium-227. Cancer Biother Radiopharm. 2020; 35(6): 437–445.
    CrossRefPubMed
  57. Abbas N, Heyerdahl H, Bruland ØS, et al. Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts. Curr Radiopharm. 2013; 6(2): 78–86.
    CrossRefPubMed
  58. First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin. https://clinicaltrials.gov/ct2/show/NCT03507452 (25.11.2021).
  59. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol. 2012; 23(Suppl 8): viii10–viii14.
    CrossRefPubMed
  60. Ralli M, Botticelli A, Visconti IC, et al. Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions. J Immunol Res. 2020: 9235638.
    CrossRefPubMed
  61. Brown MP, Bezak E, Allen BJ. The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. Melanoma Manag. 2015; 2(4): 353–366.
    CrossRefPubMed
  62. Rizvi A, Sarkar S, Goozee G, et al. Radioimmunoconjugates for targeted α therapy of malignant melanoma. Melanoma Res. 2000; 10(3): 281–289.
    CrossRef
  63. Yang DC, Chen CH. Potential new therapeutic approaches for renal cell carcinoma. Semin Nephrol. 2020; 40(1): 86–97.
    CrossRefPubMed
  64. Dengina N, Mitin T, Gamayunov S, et al. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study. ESMO Open. 2019; 4(5): e000535.
    CrossRefPubMed
  65. Brouwers AH, Mulders PFA, de Mulder PHM, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005; 23(27): 6540–6548.
    CrossRefPubMed
  66. Hagemann UB, Mihaylova D, Uran SR, et al. Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in and models of renal cell carcinoma. Oncotarget. 2017; 8(34): 56311–56326.
    CrossRefPubMed
  67. Merkx R, Heskamp S, Mulders P, et al. 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts. Med Imag Radiat Sci. 2019; 50: S1–S42.
  68. Shakil MdS, Hasan MdA, Sarker SR. Iron oxide nanoparticles for breast cancer theranostics. Curr Drug Metab. 2019; 20(6): 446–456.
    CrossRefPubMed
  69. Study of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus in subjects with bone predominant HER2 negative hormone receptor positive metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT02258451 (25.11.2021).
  70. Corroyer-Dulmont A, Valable S, Falzone N, et al. VCAM-1 targeted alpha-particle therapy for early brain metastases. Neuro Oncol. 2020; 22(3): 357–368.
    CrossRefPubMed
  71. Królicki L, Kunikowska J, Bruchertseifer F, et al. 225Ac- and 213Bi-Substance P analogues for glioma therapy. Semin Nucl Med. 2020; 50(2): 141–151.
    CrossRefPubMed
  72. Merlo A, Hausmann O, Wasner M, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999; 5(5): 1025–1033.
    PubMed
  73. Wadas TJ, Pandya DN, Solingapuram Sai KK, et al. Molecular targeted α-particle therapy for oncologic applications. AJR Am J Roentgenol. 2014; 203(2): 253–260.
    CrossRefPubMed
  74. Parker C, Lewington V, Shore N, et al. Targeted Alpha Therapy Working Group. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncol. 2018; 4(12): 1765–1772.
    CrossRefPubMed
  75. Makvandi M, Lee H, Puentes LN, et al. Targeting PARP-1 with alpha-particles is potently cytotoxic to human neuroblastoma in preclinical models. Mol Cancer Ther. 2019; 18(7): 1195–1204.
    CrossRefPubMed
  76. Królicki L, Morgenstern A, Kunikowska J, et al. Alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma multiforme. J Nucl Med. 2018; 57(Issue suppl 2): 632.
  77. Królicki L, Bruchertseifer F, Kunikowska J, et al. Safety and efficacy of targeted alpha therapy with Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2019; 46(3): 614–622.
    CrossRefPubMed
  78. Salvanou EA, Stellas D, Tsoukalas C, et al. A proof-of-concept study on the therapeutic potential of au nanoparticles radiolabeled with the alpha-emitter actinium-225. Pharmaceutics. 2020; 12(2): 188.
    CrossRefPubMed
  79. Huang X, Zhao J, Bai J, et al. Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study. J Bone Oncol. 2019; 16: 100230.
    CrossRefPubMed
  80. Subbiah V, Anderson PM, Kairemo K, et al. Alpha particle radium 223 dichloride in high-risk osteosarcoma: a phase i dose escalation trial. Clin Cancer Res. 2019; 25(13): 3802–3810.
    CrossRefPubMed
  81. Banerjee S, Parasramka MA, Paruthy SB. Garcinol: preclinical perspective underpinning chemo- and radiosensitization of cancer chapter 15. In: Role of Nutraceuticals in Cancer Chemosensitization Volume 2 in Cancer Sensitizing Agents for Chemotherapy. Elsevier Inc. 2018: 297–324.
  82. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant. 2005; 36(12): 1021–1026.
    CrossRefPubMed
  83. Jurcic JG. Targeted alpha-particle therapy for hematologic malignancies. J Med Imaging Radiat Sci. 2019; 50(4): 53–57.
    CrossRefPubMed
  84. 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome. https://clinicaltrials.gov/ct2/show/NCT03670966 (25.11.2021).
  85. Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT02928029 (25.11.2021).
  86. Saidi A, Maaland A, Torgue J, et al. Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). J Nucl Med. 2019; 60(Suppl 1): 354.
  87. Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma. https://clinicaltrials.gov/ct2/show/NCT02581878 (25.11.2021).
  88. Ruggiero A, Villa CH, Holland JP, et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine. 2010; 5: 783–802.
    CrossRefPubMed
  89. Mukherjee A, Paul M, Mukherjee S. Recent progress in the theranostics application of nanomedicine in lung cancer. Cancers (Basel). 2019; 11(5).
    CrossRefPubMed
  90. Woodward J, Kennel SJ, Stuckey A, et al. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. Bioconjug Chem. 2011; 22(4): 766–776.
    CrossRefPubMed
  91. McLaughlin MF, Woodward J, Boll RA, et al. Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS One. 2013; 8(1): e54531.
    CrossRefPubMed
  92. Guerra Liberal FDC, O'Sullivan JM, McMahon SJ, et al. Targeted alpha therapy: current clinical applications. Cancer Biother Radiopharm. 2020; 35(6): 404–417.
    CrossRefPubMed
  93. Verhoeven M, Seimbille Y, Dalm SU. Therapeutic applications of pretargeting. Pharmaceutics. 2019; 11(9): 434.
    CrossRefPubMed
  94. Harvey JT. NorthStar perspectives for actinium-225 production at commercial scale. Curr Radiopharm. 2018; 11(3): 180–191.
    CrossRefPubMed
  95. Tagawa S, Osborne J, Niaz M, et al. Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clinic Oncol. 2020; 38(6_suppl): 114.
    CrossRef
  96. Lindegren S, Albertsson P, Bäck T, et al. Realizing clinical trials with astatine-211: the chemistry infrastructure. Cancer Biother Radiopharm. 2020; 35(6): 425–436.
    CrossRefPubMed
  97. New diagnostic isotope to enhance targeted alpha therapy for cancer. https://www.itnonline.com/content/new-diagnostic-isotope-enhance-targeted-alpha-therapy-cancer (25.11.2021).
  98. Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving ac-psma-617 radioligand therapy. J Nucl Med. 2020; 61(1): 62–69.
    CrossRefPubMed
  99. A Phase 1/2 study of [225Ac]-FPI-1434 injection. https://clinicaltrials.gov/ct2/show/NCT03746431 (25.11.2021).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl